I
t sounds all too obvious: Screen people for Helicobacter pylori , a known cause of gastric cancer; then treat the infection with antibiotics and save hundreds of thousands of lives each year.
But it's not that simple, and a debate about the pros and cons of population screening and treatment for H. pylori continues to simmer. In July, a new study in The Lancet added fresh fuel to the discussion. Masahiro Asaka, M.D., of Hokkaido University Graduate School of Medicine in Japan and colleagues in the Japan GAST Study Group studied 544 patients with early gastric cancer and H. pylori infection. The patients were randomized to receive either standard care for gastric cancer or standard care plus antibiotics to eradicate the infection. Among those who took the antibiotics, nine developed new cancers compared with 14 among those receiving standard care. The difference was statistically signifi cant.
In an accompanying editorial, Nicholas Talley , M.D., Ph.D., of the Mayo Clinic in Jacksonville, Fla., wrote that the implications of the research extend beyond those with a history of gastric cancer to other high-risk groups.
"Population screening and treatment," he wrote, "should be pursued by governments in populations at very high risk, and by [ 
Pros
Arguments in favor of screening and treatment often start with the huge public health impact of gastric cancer, the fourth most common cancer in the world and the secondleading cause of cancer-related death. It kills 700,000 people annually. Many of those deaths are concentrated in high-risk areas, such as Japan, Korea, and China, so H. pylori screening programs in these countries could theoretically save many lives. Second, the evidence linking H. pylori and gastric cancer is strong. "It is almost irrefutable that H. pylori causes the disease," said Talley. The World Health Organization agrees, listing H. pylori as a carcinogen for gastric cancer. On the other hand, it is not the only cause of gastric cancer. Environmental factors such as high salt intake and host factors also play a role. H. pylori is a necessary, but not suffi cient, cause of the disease, according to the consensus report.
Third, there is a body of research suggesting that screening and treating H. pylori in high-risk groups can reduce the risk of the disease. This is one place where the debate heats up, however. No randomized trial has yet shown a statistically signifi cant benefi t for population screening and treatment. A few studies have found that eradicating H. pylori can help prevent precancerous lesions from progressing. But to date, four randomized, placebo-controlled trials in general populations in high-risk areas of Asia have shown only a non -statistically signifi cant trend toward risk reduction among those treated for H. pylori .
"There is no large, blinded, randomized, placebo-controlled trial," Talley said.
Nevertheless, he argued, the evidence is all in the right direction. And a meta-analysis conducted for the consensus conference, not yet published, has shown a statistically signifi cant benefi t, he said. It was on the basis of the studies to date plus the meta-analysis that the consensus conference experts concluded that H. pylori eradication in high-risk populations could reduce the risk of gastric cancer.
Cons
But even those convinced that screening and eradication would work admit that there are risks involved. One of these is the possibility of the organism developing increased resistance to antibiotics. The standard treatment for the infection is a 1-or 2-week course of several drugs, such as lansoprazole (which inhibits the production of acid in the stomach), and the antibiotics amoxicillin and clarithromycin. If patients do not fi nish the regimen, the bacterium could develop resistance to the medications. "This is a real problem and a real possibility," Talley said. On the other hand, the antibiotics to treat H. pylori are already How H. pylori protects against EAC has not been established, but it may have to do with the infection's suppressing acidity in the upper part of the stomach, Blaser said. When H. pylori is eliminated, the esophageal refl ux is likely to contain more acid. That in turn raises the risk of the precancerous condition known as Barrett's esophagus, which can lead to EAC.
H. pylori has also been associated with low rates of childhood asthma and other allergic conditions, according to recent studies. Blaser and colleague Yu Chen, Ph.D., also at New York University, have used data from two recent National Health and Nutrition Examination Surveys to examine the association between H. pylori infection and asthma, hay fever, and atopic dermatitis. In their most recent study, based on survey results from 1999 -2000 and published in July in the Journal of Infectious Diseases, children between the ages of 3 and 13 were 59% less likely to have asthma if they had H. pylori .
Researchers have also found that H. pylori , an ancient and well-conserved colonizer of the human gut, is much less common now in developed countries than it was a century ago, probably because of better sanitation and antibiotics. Its decline coincides with the rise of childhood asthma in the United States and elsewhere.
Different Risks
The data pointing to H. pylori ' s good side make the questions surrounding screening more diffi cult. "It is not clear that every time we fi nd H. pylori in humans it is a problem," said Andreas Ullrich, M.D., WHO's medical offi cer for cancer control.
In fact, in some parts of Asia, such as India, Pakistan, and Thailand, H. pylori rates are high, whereas gastric cancer rates are low. The reasons for this incongruity probably have to do with both host and environmental factors, experts say. For instance, life expectancy in those countries is not as high as that in countries such as Japan, and gastric cancer is a disease of old age. Diet, other common infections, and variations in strains of H. pylori could also play a role in different gastric cancer rates. In any case, it is clear that not everyone with H. pylori is at risk.
"I strongly agree that people at very high risk for gastric cancer need treatment for H. pylori ," Blaser said. "But the risk of gastric cancer is heterogeneous; it's not the same in all populations or individuals."
One way to manage the two sides of H. pylori may be to carefully select the populations to be screened and the individuals to treat. To that end, some researchers are searching for biomarkers that would tell them whether H. pylori was more likely to be a risk or a benefi t in a particular patient. "If you had a biomarker that put you at high risk for gastric cancer, you would decide to get rid of H. pylori ," Blaser said. "But if you had a biomarker that said you were at greater risk of EAC, then you might keep your H. pylori ."
Another future scenario, he speculated, might include an engineered version of H. pylori that would protect against asthma and EAC but not increase the risk of gastric cancer. In that vein, he added, "I could envision a world in which doctors give H. pylori to children to help with normal development and to help prevent asthma and then at some age, 40 or 50 maybe, when the risk of gastric cancer is higher, get rid of it."
Doing Something Now
Now, though, governments and public health groups are under increa sing pressure to do something about the death toll from gastric cancer. Proponents of mass H. pylori screening argue that the risks of EAC and other problems are not as great as the risk of gastric cancer in parts of Asia. EAC, though more common than it used to be, is still a fairly rare disease, Talley said. "I think there is a relationship there, but eliminating the scourge of gastric cancer is worth the risk." In Japan, there may soon be more discussion about H. pylori screening, according to Asaka, who heads the Japanese Society for Helicobacter Research. "We are planning to appeal to the Japanese government to make a new system through which the prevention of gastric cancer by H. pylori eradication might be achieved," he wrote in an e-mail. The society is also updating its guidelines for management of H. pylori and will recommend that it be eradicated in all persons with the infection, Asaka said. Other Asian governments have also been approached, according to Kwong Ming Fock, M.D., a professor at the National University of Singapore and one of the leaders of the consensus conference. WHO has no policy regarding H. pylori screening, Ullrich said. "We are much more interested in prevention approaches 
